Verduyn-van Weegen Felice Isabel 4

What Happened
Felice Verduyn-van Weegen, listed as a 10% owner of Evommune, reported receiving an award of 358,680 shares of Evommune (EVMN) on 2026-02-17. The reported acquisition price per share was $27.88, for a total reported value of $9,999,998. The Form 4 classifies the transaction as an award/grant (code A) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-17; Filing date: 2026-02-18 (filed the next day).
• Shares acquired: 358,680 at $27.88 each; total reported value $9,999,998.
• Transaction type: Award/Grant (A).
• Shares owned after transaction: Not specified in the filing.
• Footnote: The securities are held by LSP 7 Cooperatief U.A. (“LSP 7”). LSP 7 Management BV may be deemed to beneficially own these securities, and the managing directors Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed beneficial owners. The reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
• Timeliness: Filing appears timely (filed the day after the transaction), within normal Form 4 deadlines.

Context
This was an award/grant to an entity (LSP 7) rather than a reported open-market purchase by an executive. For retail investors, note that 10% owner filings often reflect institutional allocations or entity-level holdings and do not necessarily indicate personal trading intent by the named individual. An “A” code means shares were granted/awarded; it is not an exercise-for-cash or sale.